Wegovy Dosage Levels: What the Titration Schedule Actually Means for You

The decision your prescriber is actually making at each dose

People sometimes arrive at a consultation having read that 2.4 mg is the maintenance dose and assume the goal is to get there as quickly as possible. That's a reasonable assumption, but it misses what the schedule is designed to do. Each level exists for a reason: the lower doses let your digestive system adapt to semaglutide's effects before the dose climbs higher. Nausea, indigestion and changes in appetite are most noticeable in the early weeks, and a slow titration reduces how disruptive that feels.

At 0.25 mg your body is adjusting, not losing weight at the rate the trials measured. At 0.5 mg and 1.0 mg, appetite suppression becomes more meaningful for most people. By 1.7 mg and 2.4 mg, you're at the doses where the STEP 1 trial in the New England Journal of Medicine recorded an average weight reduction of around 15% over 68 weeks. The schedule isn't a formality, it's the mechanism that makes the treatment workable for most people who take it.

Your prescriber also monitors whether a dose increase is appropriate. If side effects are significant, staying at a lower level for longer is often the right call. That's not falling behind; it's the schedule doing its job. You can read more about how the individual Wegovy doses work in practice if you want detail on specific levels.

What the 7.2 mg approval changes, and for whom

In January 2026, the MHRA approved a 7.2 mg maintenance dose of semaglutide for adults with obesity. Initially, this was delivered as three 2.4 mg pens used in a single week. On 14 April 2026, a dedicated single-dose 7.2 mg pen was approved, one injection per week, with a built-in covered needle that locks after use. Trials reported an average weight loss of around 20.7% over 72 weeks at this higher dose, narrowing the gap with tirzepatide's results.

The 7.2 mg dose is licensed for adults with a BMI of 30 or above. It is not approved for the BMI 27–29.9 with comorbidity route, and it is not the starting point. The titration still begins at 0.25 mg and works upward in the same steps; 7.2 mg is the ceiling for those who are clinically suitable and whose prescriber judges it appropriate after reaching 2.4 mg. The MHRA's announcement of the single-dose 7.2 mg pen has full detail on what was approved and why.

Whether the higher dose is right for you is something a prescriber decides after reviewing your full picture. Specific dose and pen format availability is confirmed at consultation, we'd never tell you in advance what stock or format you'll receive, because that depends on what's clinically appropriate. For a closer look at the 2.4 mg level specifically, the Wegovy 2.4 mg page covers what that dose involves.

Eligibility, timing, and what actually triggers a dose change

Wegovy is licensed for adults with a BMI of 30 or above, or 27–29.9 alongside a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. Licensing criteria are one part of the picture; your prescriber also considers your overall health, any medicines you take, and whether the titration is proceeding safely before moving you up. A missed dose, a period of illness, or a holiday that disrupts your routine are all things worth flagging, your prescriber can advise whether to stay at your current level or adjust.

On the subject of timing: if your treatment is due around a bank holiday or at a point in the month when things feel hectic, it's worth ordering a few days early so you're not caught mid-schedule without your pen. Orders placed by 12pm Monday to Friday are dispatched the same day if clinically approved, arriving the next working day via tracked DPD delivery, that detail matters when your titration is time-sensitive.

The NHS semaglutide medicines page covers how doses are administered and what to do if you miss an injection. There's also a broader overview of how Wegovy's mg levels are structured if you want a reference alongside the SmPC. Questions about how weight-related conditions interact with hormone levels occasionally come up at this stage too, the semaglutide and oestrogen page addresses one common one.

Picking the right service matters as much as the right dose

Because these are prescription-only medicines, the clinical relationship behind your prescription shapes the whole experience. A prescriber who reviews your consultation personally (not software processing a form) can catch things that matter: a medicine interaction, a reason to pause a dose increase, a question you didn't know to ask. At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it arrives.

If cost is part of your thinking, the Wegovy price comparison page puts private UK pricing in honest context and is worth reading before you decide where to go. Wherever you end up, choosing a pharmacy you can verify on the GPhC register is the baseline check. For a full picture of what treatment involves, the Wegovy overview covers the medicine from licence to lifestyle support. And when you're ready to check whether you're eligible, starting a free consultation is the practical next step.